I
nfections due to carbapenem-resistant Gram-negative organisms represent an emerging threat to public health worldwide (1) . The majority of carbapenem-resistant Gram-negative infections are caused by nonfermenters, most commonly, Pseudomonas aeruginosa (2) . Multidrug-resistant P. aeruginosa is classified as a serious threat according to the most recent U.S. Centers for Disease Control and Prevention report, and 20% to 30% of clinical isolates are carbapenem resistant (1, 3) . Mortality associated with these infections is high (20% to 50%), making optimal and timely treatment essential (4, 5) . Unfortunately, the treatment of choice for carbapenem-resistant P. aeruginosa infection remains uncertain, and management is primarily based on pathogen-directed susceptibility patterns (6, 7) .
We conducted a single-center retrospective cohort study at Barnes-Jewish Hospital (St. Louis, MO, USA), a 1,315-bed tertiary care academic medical center, to evaluate the comparative effectiveness of antibiotic agents used in the management of sepsis due to carbapenem-resistant P. aeruginosa infection (2012 to 2015). Inclusion criteria were age Ն18 years, hospital admission, carbapenem-resistant P. aeruginosa isolated from any site, and sepsis, defined as Ն2 systemic inflammatory response syndrome (SIRS) criteria (8) . Exclusion criteria were cystic fibrosis (CF), polymicrobial infection, recurrent infection (only first case analyzed), and discharge to home alive without receiving appropriate targeted antibiotic therapy. Carbapenem resistance was defined as phe-notypic nonsusceptibility to meropenem or imipenem. Clinical data were collected retrospectively from the electronic medical record. Comorbidities were identified by diagnosis codes as recorded by a treating physician. The primary outcome was all-cause in-hospital mortality. Baseline characteristics were compared by using the chi-squared test or Fisher's exact test for categorical data and Student's t test or the Mann-Whitney U test for continuous data. Multivariable log-binomial regression analysis was conducted to determine variables associated with mortality. Susceptibility testing was performed during routine clinical care using the disk diffusion method according to Clinical Laboratory and Standards Institute (CLSI) guidelines current at the time of infection (9) . The Washington University in St. Louis institutional review board approved this study, and a P value of Ͻ0.05 was considered statistically significant.
A total of 2,736 patients with carbapenem-resistant Gram-negative infections were screened. Patients were excluded if they had Ͻ2 SIRS criteria (n ϭ 1,700), CF (n ϭ 91), recurrent infection (n ϭ 392), lack of appropriate treatment before discharge alive (n ϭ 64), and infection due to a Gram-negative organism other than P. aeruginosa (n ϭ 274). A total of 215 patients with carbapenem-resistant P. aeruginosa sepsis were included in the final analysis. Overall, in-hospital mortality was 21.4% (46/215). Factors associated with mortality are shown in The most commonly utilized treatment modality was monotherapy with cefepime (n ϭ 88). At our institution, cefepime is the treatment of choice for empirical therapy due to suspected P. aeruginosa infection, and dual Gram-negative coverage is not routinely utilized because of cefepime susceptibility rates of ϳ90% among non-CF P. aeruginosa isolates. These susceptibility rates consistently exceed those of meropenem by 5% to 10%, and it is not uncommon to encounter cases of infection due to carbapenem-resistant P. aeruginosa with retained susceptibility to other antipseudomonal ␤-lactam agents, including cefepime or piperacillin-tazobactam (our unpublished data). In a recent study at the University of Pittsburgh Medical Center, 68% of carbapenem-resistant P. aeruginosa bloodstream isolates were susceptible to cefepime, and 57% were susceptible to piperacillin-tazobactam (7) . Whether treatment of infections due to this susceptibility pattern requires use of more-toxic agents, such as aminoglycosides or polymyxins; more-expensive agents, such as novel ␤-lactam/␤-lactamase inhibitors; or combinations of multiple active agents remains unclear (10 CI, 1.04 to 1.75; P ϭ 0.003). This association persisted after adjusting for confounding factors in multivariable log-binomial regression (adjusted RR, 1.72; 95% CI, 1.03 to 2.85; P ϭ 0.037) ( Table 2 ). Other factors significantly associated with an increased risk of mortality were vasopressor requirement and comorbidity burden ( Table 2 ). In subgroup analyses by site of infection, aminoglycoside monotherapy was associated with a significantly increased risk of mortality in skin and soft tissue infections/osteomyelitis (50.0% [3/6] Only one patient with respiratory tract infection was treated with aminoglycoside monotherapy. Although aminoglycosides distribute well into various tissues, pathophysiological perturbations in critically ill patients with sepsis leading to increased volume of distribution and augmented renal clearance may decrease systemic aminoglycoside concentrations and prevent attainment of pharmacokinetic/pharmacodynamic targets versus isolates displaying MICs near the susceptibility breakpoint, potentially leading to poorer outcomes (11) .
The present study had limitations. This was a retrospective analysis at a single center and likely lacked sufficient power to detect differences between some antibiotic regimens. Thus, prospective comparative effectiveness analyses of antibiotic agents for carbapenem-resistant P. aeruginosa infection are warranted. We included culture results from all body sites to evaluate the influence of this variable on patient outcomes; however, cultures from nonsterile sites may represent colonization rather than true infection. We attempted to overcome this by limiting analyses to patients with sepsis only and excluding known colonizers (i.e., CF). Thus, we expect any degree of misclassification to be negligible. This study did not feature analyses of antibiotic dosing strategies, which may have influenced the results.
In a retrospective analysis of patients with sepsis due to carbapenem-resistant P. aeruginosa, we evaluated associations between the site of infection and antibiotic choice on all-cause in-hospital mortality. We found an increased risk of mortality among patients with respiratory tract infection and a reduced risk of mortality among patients with urinary tract infection. Aminoglycoside monotherapy was associated with higher mortality than other treatments, and the magnitude of this effect was consistent across multiple infection sites. Although additional research is needed, the present study revealed important relationships between the site of infection, antibiotic selection, and mortality in patients with carbapenem-resistant P. aeruginosa infection, which should be considered in future studies.
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